Note 1 - Organization and Business

3 Months Ended

Mar. 31, 2018

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1. Organization and Business. Amarillo Biosciences, Inc. (the "Company” or “ABI”), a Texas corporation formed in 1984, is engaged in developing biologics for the treatment of human and animal diseases. The Company’s current focus is research aimed at the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha that is administered in a proprietary low dose oral form. In addition to the above core technology, which is included in the Pharmaceutical Division, ABI is exploring the possibility of instituting new revenue streams with a Medical Division and a Consumer Products Division.

The Medical Division opened a metabolic treatment center in Hong Kong in

February 2017,

and has deployed such treatment centers in Taiwan. These centers will provide a proprietary therapy for the management of Type

1

and Type

2

diabetes along with the reversal of the complications that historically accompany this insidious disease and plague patients. Additionally, the Company is researching and implementing the treatment and management of numerous other metabolic disorders. In addition to metabolic treatment, ABI has entered the market for wound care and tissue adhesive products by in-licensing TissueAid and developing distribution channels for these products. The Consumer Product Division is presently working on a delivery system for nutraceuticals and food supplements such as Vitamin C, Glutathione,

CoQ10,

Curcumin/Resveratrol, DHA, and Multi-Vitamins; all bearing a unique, proprietary liposomal delivery system.